Anthony T Podany
Overview
Explore the profile of Anthony T Podany including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Malik J, Fletcher C, Podany A, Dyavar S, Scarsi K, Pais G, et al.
J Neurosci Methods
. 2023 Apr;
392:109867.
PMID: 37116621
The blood-brain barrier (BBB) is a protective cellular anatomical layer with a dynamic micro-environment, tightly regulating the transport of materials across it. To achieve in-vivo characteristics, an in-vitro BBB model...
12.
Virdi A, Ho S, Seaton M, Olali A, Narasipura S, Barbian H, et al.
Cells
. 2023 Apr;
12(7).
PMID: 37048107
HIV anti-retrovirals (ARVs) have vastly improved the life expectancy of people living with HIV (PLWH). However, toxic effects attributed to long-term ARV use also contribute to HIV-related co-morbidities such as...
13.
Havens J, Bares S, Lyden E, Podany A, Scarsi K, Fadul N, et al.
Open Forum Infect Dis
. 2023 Mar;
10(3):ofad080.
PMID: 36910693
Background: People with human immunodeficiency virus (HIV) and substance use disorder (PWH/SUD) are at higher risk of nonadherence to antiretroviral therapy. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) exhibits high rates of efficacy with...
14.
Scarsi K, Smeaton L, Podany A, Olefsky M, Woolley E, Barr E, et al.
Contraception
. 2023 Jan;
121:109951.
PMID: 36641094
Objectives: To determine if double-dose levonorgestrel emergency contraception (EC) in combination with efavirenz or rifampicin, 2 drugs known to decrease levonorgestrel exposure, resulted in similar pharmacokinetics compared to standard-dose levonorgestrel...
15.
Pettit A, Phillips P, Kurbatova E, Vernon A, Nahid P, Dawson R, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e580-e589.
PMID: 36041016
Background: Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and...
16.
Pham M, Podany A, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, et al.
Antimicrob Agents Chemother
. 2022 Aug;
66(9):e0238521.
PMID: 35943252
The Brief Rifapentine-Isoniazid Efficacy for TB Prevention/A5279 trial demonstrated a 1-month daily regimen of rifapentine and isoniazid was noninferior to 9 months of isoniazid alone for preventing TB in persons...
17.
Deodhar S, Sillman B, Bade A, Avedissian S, Podany A, McMillan J, et al.
Nat Commun
. 2022 Jun;
13(1):3226.
PMID: 35680875
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18-carbon chain modified ester prodrug nanocrystal (coined...
18.
Labisi T, Podany A, Fadul N, Coleman J, King K
Womens Health (Lond)
. 2022 Apr;
18:17455057221092267.
PMID: 35435055
Introduction: Women account for 23% of new human immunodeficiency virus diagnoses in the United States, yet remain understudied. Adherence to antiretroviral therapy and consequent viral suppression are keys to preventing...
19.
Ye Z, Abdelmoaty M, Curran S, Dyavar S, Kumar D, Alnouti Y, et al.
Noncoding RNA
. 2022 Jan;
8(1.
PMID: 35076584
RNA interference (RNAi) molecules have tremendous potential for cancer therapy but are limited by insufficient potency after intravenous (IV) administration. We previously found that polymer complexes (polyplexes) formed between 3'-cholesterol-modified...
20.
Podany A, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, et al.
Clin Infect Dis
. 2021 Dec;
75(4):560-566.
PMID: 34918028
Background: A 4-month regimen containing rifapentine and moxifloxacin has noninferior efficacy compared to the standard 6-month regimen for drug-sensitive tuberculosis. We evaluated the effect of regimens containing daily, high-dose rifapentine...